GE Launches $250 Million Healthymagination Fund
New equity investment fund to invest in high potential healthcare technology companies
Advertisement
GE announced the formation of the “GE Healthymagination Fund”, a new equity fund that will make investments in highly promising healthcare technology companies. The fund will invest in companies globally that have innovative diagnostic, IT, and life sciences technologies aligned with the strategic objectives of GE’s Healthymagination initiative. The fund will also support healthcare companies developing innovative and unique business models and services.
The formation of the fund is part of GE’s $6 billion Healthymagination initiative, a global commitment to deliver better healthcare to more people at lower cost. The fund will target three broad areas for investment:
- Broad-based Diagnostics, including imaging, home health, patient monitoring, molecular diagnostics, pathology, novel imaging agents and other technologies for disease diagnosis.
- Healthcare Information Technology, including electronic medical records, clinical information systems, healthcare information exchanges and value-added data services.
- Life Sciences, including tools for research and development in biopharmaceuticals and stem cells, and technologies for manufacturing of biopharmaceuticals and vaccines.
The fund will draw on capabilities from across GE Healthcare, GE Capital and GE Global Research, and will have a global footprint.
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Last viewed contents
AmpliPhi Granted European Patent for Bacteriophage Therapy to Fight Biofilm-related Bacterial Infections
Pronova BioPharma appoints Per-Oluf Olsen as new CEO
Kyowa Hakko Kogyo Co., Ltd. licenses its in-house developed antibody KW-2871 targeting malignant melanoma to Life Science Pharma
DURAN Group launches anniversary campaign to celebrate 120 years of laboratory glassware